EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury

Miguel Fontecha-Barriuso, Natalia Villar-Gomez, Juan Guerrero-Mauvecin, Julio M Martinez-Moreno iD, Susana Carrasco, Diego Martin-Sanchez, María Rodríguez-Laguna, Manuel J Gómez, María D Sanchez-Niño, Marta Ruiz-Ortega, Alberto Ortiz, Ana B Sanz iD

The Journal of Pathology · 2024-12 · 264 (4) · 396-410

DOI: 10.1002/path.6355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 29.10.2024. Verfasst von Miguel Fontecha-Barriuso und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, Madrid…. Hauptthemen laut MEDLINE: Acute Kidney Injury, Core Binding Factor Alpha 2 Subunit, Lipopolysaccharides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: COST (European Cooperation in Science and Technology), Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040, European Cooperation in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment for acute kidney injury (AKI) is suboptimal. A better understanding of the pathogenesis of AKI may lead to new therapeutic approaches. Kidney transcriptomics of folic acid‐induced AKI (FA‐AKI) in mice identified Runx1 as the most upregulated RUNX family gene. We then examined the expression of RUNX1 in FA‐AKI, in bacterial lipopolysaccharide (LPS)‐induced cytokine storm‐AKI (CS‐AKI), and in human AKI. In cultured mouse tubule cells, we explored the expression and role of RUNX1 in response to the cytokine TWEAK or LPS. A chemical inhibitor of RUNX1 (Ro5‐3335) was used in animal models of AKI to test its potential as a therapeutic target. RUNX1 overexpression in FA‐AKI was validated at the mRNA and protein levels and localized mainly to tubule cell nuclei. CS‐AKI also upregulated kidney RUNX1. Increased tubule and interstitial RUNX1 expression were also observed in human AKI. In cultured mouse tubule cells, the pro‐inflammatory cytokine TWEAK and LPS increased RUNX1 and IL‐6 expression. Mechanistically, RUNX1 bound to the Il6 gene promoter and RUNX1 targeting with the chemical inhibitor Ro5‐3335, or a specific small interfering RNA (siRNA), prevented the TWEAK‐ and LPS‐induced upregulation of IL6 through a RUNX1/NFκB1 p50 pathway. In vivo , preventive Ro5‐3335 improved kidney function and reduced inflammation in FA‐AKI and CS‐AKI. However, Ro5‐3335 administration after the insult only improved kidney function in CS‐AKI. Kidney transcriptomics identified inflammatory genes and transcription factor mRNAs such as Yap1 and Trp53 as key targets of Ro5‐3335 in CS‐AKI. In conclusion, RUNX1 contributes to AKI by driving the expression of genes involved in inflammation and represents a novel therapeutic target in AKI. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryCore Binding Factor Alpha 2 SubunitLipopolysaccharidesAnimalsHumansDisease Models, AnimalMice, Inbred C57BLFolic AcidCytokine TWEAKInterleukin-6MaleMiceKidney TubulesSignal Transduction

Stichwörter der Autor:innen

LPSRUNX1Ro5‐3335TWEAKacute kidney injuryinflammation

Substanzen

Core Binding Factor Alpha 2 SubunitRUNX1 protein, humanRunx1 protein, mouseLipopolysaccharidesFolic AcidCytokine TWEAKInterleukin-6Tnfsf12 protein, mouseinterleukin-6, mouse

Autor:innen und Institutionen

  • Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, Madrid, Spain.
  • RICORS2040, Madrid, Spain.
  • Unidad de Reumatologia, Hospital Clinico San Carlos, Madrid, Spain.
  • Unidad de Bioinformatica, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Department of Pharmacology, Universidad Autonoma de Madrid, Madrid, Spain.
  • Department of Medicine, Universidad Autonoma de Madrid, Madrid, Spain.

ORCID-Profile: Julio M Martinez-Moreno, Ana B Sanz

Förderung

  • COST (European Cooperation in Science and Technology)
  • Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040
  • European Cooperation in Science and Technology
  • Instituto de Salud Carlos III

Zitieren

APA

Fontecha-Barriuso, M., Villar-Gomez, N., Guerrero-Mauvecin, J., Martinez-Moreno, J. M., Carrasco, S., Martin-Sanchez, D., Rodríguez-Laguna, M., Gómez, M. J., Sanchez-Niño, M. D., Ruiz-Ortega, M., Ortiz, A., & Sanz, A. B. (2024). Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury. The Journal of Pathology, 264(4), 396-410. https://doi.org/10.1002/path.6355

Vancouver

Fontecha-Barriuso M, Villar-Gomez N, Guerrero-Mauvecin J, Martinez-Moreno JM, Carrasco S, Martin-Sanchez D, et al. Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury. The Journal of Pathology. 2024;264(4):396-410. doi:10.1002/path.6355

BibTeX
@article{FontechaBarriuso2024,
  author = {Fontecha-Barriuso, Miguel and Villar-Gomez, Natalia and Guerrero-Mauvecin, Juan and Martinez-Moreno, Julio M and Carrasco, Susana and Martin-Sanchez, Diego and Rodríguez-Laguna, María and Gómez, Manuel J and Sanchez-Niño, María D and Ruiz-Ortega, Marta and Ortiz, Alberto and Sanz, Ana B},
  title = {Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury},
  journal = {The Journal of Pathology},
  year = {2024},
  volume = {264},
  number = {4},
  pages = {396--410},
  doi = {10.1002/path.6355}
}
Kostenlos starten →